Skip Navigation
  • Text Size: A A A
  • Print
  • Email
  • Facebook
  • Tweet
  • Share
  • Print
  • Email
  • Facebook
  • Tweet
  • Share

Testimony

Statement by
RADM W. Craig Vanderwagen, M.D.
Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

on
Safeguarding our Nation: HHS Emergency Preparedness Efforts 

before
Committee on Homeland Security
Subcommittee on Emerging Threats, Cybersecurity, Science, Technology and Government Affairs
U.S. House of Representatives


Tuesday July 22, 2008

Good Morning Chairman Langevin, Mr. McCaul, and Members of the Committee. I am RADM W. Craig Vanderwagen, M.D., the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). I appreciate this opportunity to discuss the HHS plans and initiatives in public health and emergency preparedness to respond to emerging biological threats, including pandemic influenza. HHS’s Office of the ASPR has adopted an “all-hazards” approach to our preparedness and response activities, moving us from stand alone plans to a process that addresses all of the hazards that potentially threaten the public’s health. We have collaborated and coordinated closely with our Federal interagency partners and have provided States and municipalities with funding to enhance their public health and medical preparedness.

Emergency Preparedness

Our “all-hazards” preparedness involves a shared responsibility among our entire Department, our partners in the international community, the Federal, State, local, Tribal and Territorial governments, the private sector, and, ultimately, individuals and families. Additionally, before an event, government agencies at all levels work with the private sector to plan and exercise so they can be ready when a disaster occurs. During an emergency, local and State response agencies, including public health departments, are the first to respond. For regional or severe emergencies, the Federal government may be asked to provide additional resources and coordinate response efforts across multiple jurisdictions.

In that context, some of the emergency preparedness efforts currently being led by HHS involve working with our Federal, State, and local partners. For instance, we support State and local authorities through the Hospital Preparedness Program and the Public Health Emergency Preparedness Program for a broad range of medical and public health preparedness activities, including the development of medical and public health plans for response, increasing the number of exercises to evaluate these plans, increasing the training opportunities in key preparedness areas, increasing epidemiological and laboratory detection capabilities, establishment of local stockpiles of critical medical equipment and supplies, improving surveillance and investigation capabilities, maintenance and distribution of countermeasures, and sharing of resources.

Emergency Support Function #8 – Public Health and Medical Services

The National Response Framework (NRF) Emergency Support Function (ESF) #8 – Public Health and Medical Services – provides the mechanism for coordinated Federal assistance to supplement State, local, Tribal, and Territorial resources in response to a public health and medical disaster, potential or actual incidents requiring a coordinated Federal response, and/or during a developing health and medical emergency. The Secretary of HHS; here forth the Secretary, leads all Federal public health and medical response to public health emergencies and incidents covered by the NRF The response addresses medical needs and other functional needs of those requiring medical care and other assistance during an emergency.

Except for the personnel and assets under the command of the Department of Defense, the Secretary assumes operational control of Federal emergency public health and medical response assets, as necessary, in the event of a public health emergency. The Secretary, through ASPR, coordinates National ESF #8 preparedness, response, and recovery actions.

HHS has implemented an incident command system that is National Incident Management System compliant. Additionally, all states have established emergency operation centers and have also implemented an incident command system. We have trained and equipped response personnel who include not only the National Disaster Medical System (NDMS) teams, but also Public Health Service Commissioned Corps Officers.

The operational command of personnel deployed under our auspices is fully consistent with and supportive of the Department of Homeland Security’s (DHS’s) role as overall incident manager, including liaisons in the National Operations Center, National Response Coordination Center, and the Joint Field Office. The HHS recognizes and supports the overall lead of DHS in coordinating the Federal response and we take seriously our role as the lead Federal agency for Public Health and Medical Services through ESF #8, of the NRF.

Pandemic and All-Hazards Preparedness Act (PAHPA)

Consistent with requirements contained in the Public Health Service Act, as amended by the Pandemic and All-Hazards Preparedness Act (PAHPA), HHS has updated the performance measures for both the Hospital Preparedness Program and the Public Health Emergency Preparedness Program. Specific improvements include greater clarity in language, the use of definitions, and the addition of targets. For example, in FY 2006, HHS asked grantees to report participating hospitals' ability to track bed status electronically, and report it to the grantee's Emergency Operations Center within 60 minutes of a request. In 2007, the numerator and denominator were defined to improve clarity. For FY 2008, the target percentage of hospitals able to report was increased to 100 percent by the end of the end of the year.

HHS strongly supported the new accountability provisions included in PAHPA and is implementing these provisions. First, FY 2009 award funds will be based on the successful achievement of targets during the previous budget cycle. In addition, the matching provision will be applied to the Public Health Emergency Preparedness Program (PHEP) in FY 2009. We also intend, through notice and comment, to apply the matching provision to the Hospital Preparedness Program (HPP) in FY 2009. The audit and carryover provisions apply to both the PHEP and HPP programs currently; the withholding provision will be applied to these programs in FY 2009. The HPP and PHEP programs implemented the maintenance of funding provision in FY 2007.

Public Health Emergency Preparedness (PHEP) Program

From FY 2002- FY 2008, the Public Health Emergency Preparedness (PHEP) program has provided $6.3 billion to State, local, Tribal, and Territorial public health departments. This amount includes targeted supplements to prepare for smallpox (in FY 2003) and for an influenza pandemic (FY 2005 – FY 2007). This program has greatly increased the preparedness capabilities of public health departments:

  • All States can receive and evaluate urgent disease reports 24/7, while in 1999 only 12 could do so.
  • All States now conduct year-round influenza surveillance.
  • The number of State and local public health laboratories that can detect biological agents as members of CDC’s Laboratory Response Network (LRN) has increased to 110 in 2007, from 83 in 2002. For chemical agents, the number increased to 47, from 0 in 2001. Rather than having to rely on confirmation from laboratories at CDC, LRN laboratories can produce conclusive results. This allows local authorities to respond quickly to emergencies.
  • All States have trained public health staff roles and responsibilities during an emergency as outlined in the Incident Command System, while in 1999 only 14 did so.
  • All States routinely conduct exercises to test public health departments’ ability to respond to emergencies. Such exercises were uncommon before PHEP funding.

Hospital Preparedness Program (HPP)

We have made considerable investments in building the healthcare preparedness and response capabilities required during an incident resulting in mass casualties, and are committed to performance measurement. Over the past five years, the Hospital Preparedness Program (HPP) has provided more than $2.6 billion to fund the development of medical surge capacity and capability at the State and local level. As a result of HPP funds awarded to States and Territories, hospitals and other healthcare entities:

  • Increased their ability to provide needed beds during an emergency;
  • Can now track bed and resource availability using electronic systems;
  • Engaged with other responders through interoperable communication systems;
  • Appropriately train their healthcare workers for all-hazards approach to emergencies,
  • Protect their healthcare workers with proper equipment;
  • Have installed equipment necessary to decontaminate patients;
  • Have developed fatality management and hospital evacuation plans, and
  • Coordinate regional exercises.

Regional Emergency Coordination

HHS has worked diligently to partner with State, Tribal, Territorial, and local officials to enhance their level of preparedness and to ensure they can see how HHS will respond to disasters. Our Regional Emergency Coordination/Coordinator (REC) program has been enhanced. In the past year, we have increased the number of RECs from 10 to over 30. The REC’s role is to work with the States and local jurisdictions to coordinate and enhance preparedness within the region. I have personally been to each of the 10 HHS regions to participate in local exercises and meet with State and local health leadership to discuss the level of preparedness and how HHS can support them.

US Public Health Service, Volunteer Personnel

HHS has a number of resources that are rapidly available to deploy in response to a biological event. The full-time U.S. Public Health Service (USPHS) responders include the Rapid Deployment Force (RDF) Teams, Applied Public Health Teams (APHT), Mental Health Teams (MHT) and additional USPHS Officers. Volunteer healthcare professionals are available through the Medical Reserve Corps, which has over 160,000 members in approximately 700 teams. The Emergency System for Advance Registration of Volunteer Health Professionals (ESAR-VHP) ensures the availability of volunteers for quick exchange between jurisdictions.

National Disaster Medical System

We are also continuously improving HHS’s operational capabilities to respond to emergencies. The NDMS, transferred from the Department of Homeland Security to HHS, remains the “tip of the spear” as the Federal disaster healthcare response capability, maintaining 6,200 medical and public health professionals and over 1,800 participating hospitals that offer definitive care services, with approximately 34,000 available beds (at most recent count). NDMS field teams include the Disaster Medical Assistance Teams (DMAT), Disaster Mortuary Operational Response Teams (DMORT), National Medical Response Teams (NMRT), and International Medical and Surgical Response Teams (IMSRT).

Since the transfer of NDMS last year, we have achieved a number of accomplishments aimed at improving the System including the integration of NDMS into the larger ESF# 8 response framework and regionalization of NDMS response operations and caches to provide increased accountability and standardization for supplies as well as fiscal savings. Future goals for NDMS include enhancing readiness and accountability through regionalization of NDMS response operations and enhancing equipment caches.

Federal Medical Stations

The HHS Federal Medical Station (FMS) is a deployable healthcare platform that can provide non-acute hospital bed surge capacity and special medical needs sheltering. A standard FMS can house approximately 250 patients and is staffed by the Rapid Deployment Force teams. The FMS are useful in care of patients with suspected or confirmed exposure to biological threats, and who may require for example, observation, limited definitive care, or primary care.

Playbooks

HHS prepares playbooks for the different scenarios of man-made and natural disasters. For biological emergencies response there are separate playbooks including anthrax, Clostridium botulinum, small pox, and pandemic influenza. These playbooks are used by HHS during an event and include sections for the:

  • Scenario;
  • Concept of operations, or CONOPs, for the response ;
  • Action steps;
  • Briefing and decision papers; and
  • Essential elements of information.

The action steps are time-oriented, and include pre-event steps should there be credible intelligence that the risk of an event is high. The action steps are arranged into natural stages for a response and include a trigger for each stage, a recommended strategy to follow, and specific actions to take.

ASPR has written and exercised playbooks based on 11 of the 15 National exercise scenarios. The process of developing these playbooks provides opportunities for input from our ESF #8 Federal partners. Additionally, HHS playbooks, starting with the hurricane playbook, will be placed on the HHS web site to facilitate their examination and use by State, local, Tribal, and Territorial, officials. We will make additional playbooks available as they become ready for release.

The Medical Response System for TRiage, TRansport, TReatment

HHS has developed a response system called the TR system for Treatment, Triage and Transport in an event, that takes into account the factors and character of the agent or threat, in determining medical response. The triage of individuals will be based on medical evaluation including where they were during and shortly after the event with particular attention to special needs that they may have. The initial triage will attempt to separate people into three broad categories:

  • those needing immediate medical attention, which would include those with clinical effects of known exposure to a biological agent or highly suspect exposure risk;
  • those without clinical effects to the biological agent but at risk from potential exposure (due to location, etc.);
  • those with minimal or no likelihood of exposure and no clinical effects from the biological agent, who do not require immediate medical care.

MedMap

HHS is developing an interactive geographic information system (GIS)-based mapping system, called MedMap, which will include data for resources in a response to any type of hazard such as potential medical care sites and assembly centers in the U.S., evacuation routes, hazards, etc. so that up-to-date information will be immediately available by which to organize the response.  Determining which local medical care and assembly center facilities are functional or not in the exposure area is essential, as is having information on what regional and nationwide resources are available.

Response Operations

HHS maintains an operations center 24/7/365. The Secretary’s Operations Center (SOC) is directly connected to the DHS National Operations Center and the FEMA National Response Operations Center. It serves as the focal point for situational awareness, information management and response coordination for HHS. We have established relationships with subject matter experts from within HHS Operating and Staff Divisions such as NIH, CDC, FDA, and ASPR.

Homeland Security Presidential Directive #18

In January, 2007 the President issued Homeland Security Presidential Directive (HSPD) #18, which directed the Secretary and the Federal Government in development and acquisition of medical countermeasures for weapons of mass destruction. The HSPD-18 builds on the National Strategy to Combat Weapons of Mass Destruction and Biodefense for the 21st Century by focusing on medical countermeasure research, development, and acquisition efforts. The HSPD-18 objectives for countermeasure include (1) identification of target threats with potential for catastrophic impact on public health and able to be mitigated; (2) yielding rapidly deployable and flexible capabilities to address threats; (3) integration with WMD consequence management through risk assessments of threats, vulnerabilities, and capabilities; and (4) development of realistic, effective concepts of response for an attack. With this in mind, the research, development, acquisition of medical countermeasures is driven by principles that focus on (1) current and anticipated threat agents with greatest potential for use, and catastrophic consequences; (2) greatest potential to prevent, treat, and mitigate WMD threats; and (3) integration with effective deployment strategies supportable by realistic current or future operational and logistical capabilities.

The biological threats focus of HSPD-18 addresses four distinct categories which present unique challenges and significant opportunities for development of medical countermeasures. 

(1) Traditional agents are naturally occurring microorganisms or toxins with the potential to be disseminated to cause mass casualties. Such agents include Yersinia pestis, plague; and Bacillus anthracis, anthrax.

(2) Enhanced Agents are modified or selected traditional agents that enhance their ability to cause mass casualties. Such agents would include antibiotic resistant organisms that as such, circumvent medical countermeasures.

(3) Emerging Agents are pathogens that previously did not pose a recognizable risk to human populations, but are now identified to pose this risk, such as Severe Acute Respiratory Syndrome (SARS).

(4) Advanced Agents are novel pathogens or biomolecules that have been artificially engineered, and can circumvent current medical countermeasures to produce a more severe or enhanced spectrum of disease.  In a way, genetically engineered smallpox strains could fit under this guise, as would engineered Ebola strains.

The HSPD-18 authorizes the Secretary to lead Federal Government efforts to research, develop, and acquire medical countermeasures via establishment of an interagency committee to provide advice in setting medical countermeasure requirements, research, development, and procurement activities; and establishment of a strategic planning initiative to integrate requirements, development and acquisition of countermeasures across the full range of research and life cycle development. The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and the PHEMCE Strategy and Implementation Plan for CBRN Threats address these directives respectively.

Medical Countermeasures

Biomedical Advanced Research and Development Authority – Development and Acquisition

Our progress in securing medical countermeasures begins with and depends on effective planning. The central framework for medical countermeasures planning and implementation in the Federal government is the HHS PHEMCE, established in July 2006. This coordinated interagency group is led by the ASPR, and includes the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) as well as our partners from the Department of Defense (DOD), DHS, and Department of Veterans Affairs (VA). Through this Enterprise-wide effort, we are able to ensure that Federal activities with respect to needed medical countermeasures are effectively coordinated from research and development to acquisition and ultimately deployment. This supports a range of programs that I will briefly summarize for developing and acquiring medical countermeasures for man-made and naturally-occurring public health threats while building domestic manufacturing infrastructure.

HHS established the Biomedical Advanced Research and Development Authority (BARDA) to direct and coordinate the Department’s countermeasure and product advanced research and development activities. In support of the mission and priorities of PHEMCE, BARDA establishes systems that encourage and facilitate the development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of chemical, biological, radiological and nuclear (CBRN) agents and emerging infectious diseases, including pandemic influenza. The BARDA provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies and diagnostic tools for public health emergencies. It directs and coordinates the Department’s countermeasure and product advanced development activities and medical countermeasure domestic manufacturing infrastructure building, including strategic planning for medical countermeasure research, development, and procurement. This coordinated approach is critical to achieving success in the area of bioterrorism preparedness.

Anthrax: Anthrax remains a top priority for ongoing public health emergency preparedness efforts at HHS. The Department is committed to developing and acquiring a robust, comprehensive portfolio of medical countermeasures against this threat. Antibiotics represent the first line of defense to protect the nation following an anthrax attack. Today, we have over 60 million courses of antibiotics on hand and on order for the Strategic National Stockpile (SNS).  Anthrax vaccines are also an essential element of our national preparedness. It is possible that vaccines given as post-exposure prophylaxis in combination with antibiotics could provide longer-term protection, or allow for a reduction in the duration of the antibiotic regimen. HHS has awarded contracts for the acquisition of nearly 30 million doses of anthrax vaccine since 2005, including the recent contract award of 18.75 million doses of Anthrax Vaccine Adsorbed (AVA, BioThrax™) in partnership with the DoD. In addition, antitoxins are necessary to treat individuals with advanced stages of infection, and may contribute to a more successful therapeutic outcome. Beginning in 2007, HHS has awarded contracts to two manufacturers to deliver antitoxins sufficient for treating 30,000 people. These vaccine and antitoxin contracts were awarded under the authorities of the Project BioShield Act of 2004. In addition, three BARDA contracts for the advanced development of other anthrax therapeutic candidates were recently awarded through a partnership with the NIH/ National Institute of Allergy and Infectious Diseases (NIAID).

HHS remains committed to the development and acquisition of a second generation anthrax vaccine. While procuring and continuing to improve the currently available anthrax vaccine, HHS is investing over $40 million in the continued development of a recombinant anthrax vaccine. This investment builds on the recombinant vaccine program that has been ongoing at the NIAID since 2002. BARDA also released a Request for Proposals (RFP) in March 2008 for a recombinant anthrax vaccine contract award. In addition, BARDA and NIAID released a Broad Agency Announcement in September 2007 for vaccine enhancement that will support important improvements in storage conditions and administration for vaccines against a wide array of biological threats; these proposals are currently under USG review.

Smallpox virus: In June 2007, BARDA awarded a contract for a next generation modified vaccinia Ankara (MVA) smallpox vaccine for use in immune-compromised Americans. This was the first BARDA contract to utilize performance-based milestone payments allowable under the Pandemic and All Hazards Preparedness Act (PAHPA). HHS/CDC has also procured ACAM-2000, a live, single-dose smallpox vaccine developed by Acambis, which is the first new bio-defense vaccine to be approved by the FDA.

Botulinum toxin: In June 2006, HHS awarded a contract under Project BioShield to the Cangene Corporation for 200,000 doses of a botulinum antitoxin that targets all 7 serotypes of Clostridium botulinum. The $363 million contract will expand greatly our existing stockpiles in the SNS. Deliveries of this product to the SNS initiated in 2007.

Pandemic Influenza: The pandemic influenza program is focused on vaccines, antivirals, diagnostics, and non-pharmaceutical countermeasures. In December 2005, and June 2006, Congress appropriated $5.6 billion for HHS pandemic influenza preparedness efforts. With these funds, scientists and public health experts at HHS have built an aggressive and broad-based medical countermeasures program for pandemic influenza. These funds support the acquisition of existing products, advanced development projects to produce modernized and next-generation countermeasures, and the retrofitting and construction of the facilities necessary to produce pandemic influenza vaccines.

With respect to vaccines, HHS has a number of efforts underway. These efforts supported the first U.S. licensure of an H5N1 vaccine in April 2007, which was highlighted as the number one medical breakthrough of 2007. By the end of 2007, HHS in coordination with DoD had stockpiled 12 million courses of pre-pandemic H5N1. However, maintaining a domestic production capability for these priority countermeasures is also an essential component of the pandemic influenza preparedness strategy. In May 2006, HHS awarded five contracts for over $1 billion to GlaxoSmithKline, MedImmune, Novartis (formerly Chiron), Solvay, and Dynport (with Baxter) for support of advanced development of cell-based influenza vaccines toward U.S. licensure and expanded domestic vaccine manufacturing surge capacity.  In June 2007, we awarded two contracts for the retrofitting of existing domestic biological manufacturing facilities to produce egg-based influenza vaccines and included warm base operations for up to five years. Additionally, contract awards are expected in 2008 for the construction of new domestic facilities for manufacturing cell-based influenza vaccines that is expected to quadruple the domestic pandemic vaccine manufacturing surge capacity by 2012.

A robust and groundbreaking advanced development program has led to the rapid maturation of modernized cell-based influenza vaccine production and antigen-sparing technologies. New combinations of adjuvants and products provided by multiple manufacturers are currently supported by performance-driven milestone contracts. More rapid vaccine production may be afforded by the development of next generation recombinant influenza vaccines, which HHS will support.

Antiviral drugs have become an increasingly important medical countermeasure for influenza. Today, in coordination with DoD and VA, the SNS contains 50 million treatment courses of antiviral drugs, completing the Federal stockpile one year ahead of schedule. HHS has also supported antiviral stockpiling at the State level. Through a Federally subsidized program, States have purchased 22 million treatment courses of influenza antiviral drugs to date and are expected to reach our goal of 31 million courses by the end of 2008.

The nature of severe influenza infections has also required us to focus on preparedness through non-pharmaceutical countermeasures, such as ventilators which play an essential role in the health care of critically ill patients. The FY 2009 President’s Budget includes $25 million to develop ventilators that are more amenable to public health emergency use. This presents a prime example of the integrative, all-hazards approach that the PHEMC Enterprise seeks. A more portable and easier to use ventilator could be an essential tool for responding to many different public health threats, when having a sufficient supply of ventilators could have an impact on the morbidity and mortality of exposure.

Medical Countermeasures

Strategic National Stockpile – Distribution and Dispensing

The Division of Strategic National Stockpile (DSNS) at CDC can deploy medical countermeasures rapidly after notification to do so. In addition to medical countermeasures that can be tailored to meet the event’s specific needs, the DSNS inventory contains supplies and materiel required in the medical management of burns, trauma, injuries that may be seen in conjunction with explosive threats.

The collaborative arrangements DSNS has with a variety of agencies, corporations, companies, and organizations are essential to not only increase the ability of state and local public health agencies to dispense medical countermeasures in a timely manner but also are critical to identifying and overcoming many of the inherent challenges. The broadness of the partnership is vital in that each of the participants brings not only a different perspective to the challenges but also expands the possibilities for finding answers to breach obstacles and barriers. Developing partnerships with private and public sector agencies to sponsor closed points of dispensing (PODs) is necessary to alleviate the burden on PODs for the general public. Lightening the load on these general public PODs reduces many of the challenges faced by local health agencies, i.e., staffing, security. These partnerships also reflect the directives within HSPD-21 and PAHPA to cultivate, enhance, and maintain interagency collaboration.

An example of this collaborative partnership is demonstrated as CDC/COTPER work with the Business Executives for National Security (BENS) to promote the involvement of private corporations in preparedness planning and response. BENS is working with the State of Georgia and Los Angeles County to establish a model system, to hopefully be duplicated nationally, of corporate points of dispensing. This pilot initiative is funded through the CDC PHEP Cooperative Agreement.  BENS officials presented and networked with state and local planners at all four regional Cities Readiness Initiative workshops.

Homeland Security Presidential Directive #21

On October 18, 2007 President Bush signed HSPD #21, “Public Health and Medical Preparedness,” establishing a new National Strategy for Public Health and Medical Preparedness (the Strategy).

As directed by HSPD-21, HHS has been successful in establishing two advisory committees. The National Biosurveillance Advisory Committee has been established as a subcommittee to the CDC Advisory Committee to the Director (ACD) and a Disaster Mental Health Advisory Committee is being established as a subcommittee under the National Biodefense Science Board (NBSB) which advises the Secretary. Additionally, HHS leads the development of a national strategy on biosurveillance through CDC’s efforts and creation of the Biosurveillance Coordination Unit charged with coordinating the necessary activities to address the mandates of HSPD-21 in the development of a strategy and implementation plan for the nation’s next-generation biosurveillance capability.

Under the leadership of CDC, the HSPD-21 requirement to ensure the adequate flow of information before, during, and after an event, including critical biosurveillance data and risk analysis has quickly drafted a strategic plan of national scope. Planning is being undertaken using a broad collaborative approach that will increase stakeholder buy-in, assure effective implementation, and guide the strategic allocation of resources.

Also delegated to CDC leadership, HSPD-21 requirements pertaining to 48-hour post attack countermeasure distribution are being addressed through the strategic development of new models of distribution and dispensing of medical countermeasures that would enhance and improve the existing capabilities of the DSNS and its state and city partners. New models can incorporate other partners into a national network, including the CDC Laboratory Network, Department of Veterans Affairs, businesses, and hospital and pharmaceutical distribution systems.

Tasked to DHS leadership, HSPD-21 requirements for health risk and threat briefings to non-health political leaders at the state and city level are being met with active involvement of HHS health experts.

Finally, HHS is implementing HSPD-21 through the establishment of the Emergency Care Coordination Center (ECCC). This new center, an intradepartmental and interdepartmental collaborative effort involving the DOD, DHS, Department of Transportation and VA, will serve as the coordinating focal point for an Emergency Care Enterprise, coordinating with the Federal Interagency Committee on Emergency Medical Services. Its vision is exceptional daily emergency care for all persons of the United States and its mission is to promote Federal, State, local, tribal and private sector collaboration to support and enhance the nation’s emergency medical care.

The ECCC will assist the US Government with policy implementation and guidance on daily emergency care issues and promote both clinical and systems-based research. Through these efforts, ASPR and its Federal partners will improve the effectiveness of pre-hospital and hospital based emergency care by leveraging research outcomes, private sector findings and best practices. The ECCC will promote improved daily emergency care capabilities to improve resiliency of our local community healthcare systems. This will provide a stronger foundation on which to advance disaster preparedness efforts and strengthen our Nation’s ability to respond to mass casualty events. Currently, the ECCC Charter is being finalized and we anticipate having the Center up and running by the end of the year.

Global Health Coordination

In addition to these domestic efforts, other approaches to improving our national capabilities include partnering with allied nations. At the recent Global Health Security Action Group ministerial meeting, there was some consideration paid to the possibility of establishing international laboratory networks among the member nations. Links with Canada would be particularly useful given the geographic proximity. Informal discussions among the scientists and subject matter experts have been ongoing for a few years but no formal arrangements have been made. We continue to explore possibilities that serve the national interest.

Conclusion

HHS staff work diligently to progress and expand the initiatives in public health and emergency preparedness for emerging biological threats. We continue to assess potential biological threats in the context of an all hazards approach, and compare the plans and programs available to us for mitigating these threats to ensure we are focused on the right initiatives. Through cooperation with our Federal partners, and State, local, Tribal, and Territorial governments, we have implemented a number of preparedness programs and assets that have strengthened our ability to respond to a biological event.

Thank you for your time and interest. I am happy to answer any questions.

Last revised: June 18, 2013